Our results support the emerging paradigm that chemotherapy-activated CAFs contribute to tumor progression and that targeting the paracrine signaling mediated by activated CAFs may improve the therapeutic effects in ESCC. Here, TBX1 is linked to esophageal squamous cell carcinoma.